Physician profile
Michael Silverstein
NPI 1063440170
$974.87
in general payments reported to CMS, 2019-2025
16 companies · $405 in 2025
The $405 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $28.10 · 2021: $25.81 · 2022: $37.77 · 2023: $123 · 2024: $221 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $397.69 | 2023-2025 | Veozah |
| Millicent US INC | $121.54 | 2024-2025 | Femlyv, Intrarosa |
| Coopersurgical, INC. | $74.26 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $69.44 | 2023 | |
| Organon LLC | $55.37 | 2024-2025 | Nexplanon |
| Abbvie INC. | $52.86 | 2020-2025 | Liletta |
| Duchesnay USA Incorporated | $45.15 | 2019 | |
| Merz North America, INC. | $25.81 | 2021 | |
| Exeltis, USA INC. | $22.70 | 2025 | Slynd |
| Evofem Biosciences, INC. | $20.88 | 2022 | |
| Scynexis, INC. | $16.89 | 2022 | |
| Therapeuticsmd, INC. | $16.11 | 2019 | |
| Allergan, INC. | $15.88 | 2019 | |
| Merck Sharp & Dohme LLC | $15.02 | 2020 | |
| Hologic Sales and Service, LLC | $12.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.